News

The deal, which covers commercial, clinical and research-stage oncology portfolio, consists of an upfront payment of $1.8bn. Agios is also eligible to secure up to $200m in regulatory

Conducting the study in New Mexico will allow for the collection of data on the effectiveness and safety of bamlanivimab in a real-world setting that includes a diverse population and

The EIB’s new EUR 50 million pharmaceutical investment initiative, initiated together with kENUP Foundation, will contribute to reducing dependency on drug imports and address medical supply chain weaknesses

As per the EUA, the mRNA-1273 vaccine can be administered to individuals aged 18 years or older. Following the EUA, Moderna has commenced delivery of the Covid-19 vaccine

“We were grateful for the opportunity to present the clinical data package for our mRNA vaccine against COVID-19 to the FDA’s advisory committee today. We thank the committee

This sBLA is based on data from the pivotal Phase 3 KEYNOTE-590 trial, in which KEYTRUDA plus chemotherapy demonstrated significant improvements in the primary endpoints – overall survival

Lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), may lead to end-stage kidney disease. Benlysta, a BLyS-specific inhibitor, is a human monoclonal antibody

These positive results were observed in the mismatch repair proficient (pMMR) subgroup and the intention-to-treat (ITT) study population, which includes both patients with endometrial carcinoma that is pMMR

The financing round was led by EcoR1 Capital, with participation from existing investors Redmile Group, Samsara BioCapital, Cormorant Asset Management and an undisclosed leading healthcare investment fund. New